Orexo and Swedish Orphan Biovitrum (Sobi) have agreed to advance their exploratory feasibility study with AmorphOX initiated last year.
The feasibility study primarily assessed whether the biomolecule could be formulated in AmorphOX with retained activity. The continued collaboration will evaluate if the AmorphOX technology could add unique properties to one of Sobi’s biomolecules.
Orexo has tested enzymes, peptides and proteins in AmorphOX and seen retained activity and significant improvement in stability compared to other formulations in a wide range of storage temperatures. A core strategy to expand the use of AmorphOX is to test AmorphOX in combination with molecules controlled by other companies. Sobi is the second company agreeing to advance the project beyond the initial exploratory feasibility study, states the company.
The collaboration is still in an early development stage, but with the ambition to continue show successful results, the collaboration has the potential to proceed into a development program of a new and differentiated pharmaceutical product.”
“Advancing the collaboration is another proof of concept for AmorphOX and with the combined expertise of the companies I am certain we can learn more about the value potential for our scalable drug delivery platform. The collaboration is still in an early development stage, but with the ambition to continue show successful results, the collaboration has the potential to proceed into a development program of a new and differentiated pharmaceutical product,” says Nikolaj Sørensen, President and CEO of Orexo.
Photo of Nikolaj Sørensen: Orexo
